Pharmaceutical executives are reallocating clinical research budgets to capture market share in oral peptide and small-molecule metabolic treatments.
Pipeline Restructuring and Clinical Trial Capacity
R&D spending on traditional cardiovascular and metabolic compounds fell 9% as capital gravitated toward phase-three trials for once-daily oral GLP-1 candidates showing superior patient adherence rates.